Novel Gene Therapy AVGN7.2 Shows Promising Safety Profile in Preclinical Study for Inclusion Body Myositis
核心洞察
AVGN7.2 (搜索), a novel gene therapy utilizing AAV6 vectors and muscle-specific CK8 promoter, demonstrated excellent safety and tolerability in a 91-day mouse toxicology study with no adverse effects at doses up to 2.1×10¹⁴ vg/kg.
The therapy specifically targets muscle tissue while avoiding off-target effects, with biodistribution studies confirming muscle-specific expression of human SMAD7 (搜索) protein despite vector presence in liver and other organs.
Inclusion body myositis (搜索) affects 25-46 per million people over 50 years old and currently has no approved pharmacological treatments, making AVGN7.2 (搜索) a potential breakthrough for this orphan disease indication.
Researchers have reported promising preclinical safety data for AVGN7.2 (搜索), a novel gene therapy designed to treat sporadic inclusion body myositis (搜索) (IBM (搜索)) and other muscle wasting diseases (搜索). The comprehensive 91-day toxicology study in mice, conducted under Good Laboratory Practice standards, found no adverse drug-related effects at any tested dose level, representing a significant milestone in the development of treatments for this debilitating condition.
Addressing an Unmet Medical Need
Sporadic inclusion body myositis (搜索) represents the most common acquired idiopathic inflammatory myopathy in people over 50 years of age, with an estimated prevalence of 25-46 per 1,000,000 individuals. The disease primarily affects middle-aged and elderly patients, with approximately 70% being male and a mean onset age of 60 years. Patients typically experience progressive muscle wasting that begins in finger and wrist flexors, knee extensors, and ankle dorsiflexors before developing into systemic muscle deterioration.
Currently, no pharmacological therapy exists for treating IBM (搜索), despite the severe disability and increased mortality associated with respiratory failure, pneumonia, and dysphagia that characterize the disease's progression. Traditional corticosteroid treatments are no longer recommended due to lack of empirical support and potential for inducing skeletal and cardiac muscle atrophy, making IBM a condition that satisfies criteria for rare disease status.
Innovative Gene Therapy Design
AVGN7.2 (搜索) represents a second-generation gene therapeutic that builds upon earlier research with AVGN7. The therapy utilizes adeno-associated virus serotype 6 (AAV6) vectors combined with a muscle-specific CK8 promoter to deliver a codon-optimized human SMAD7 (搜索) gene specifically to striated muscle tissue.
Previous studies with the first-generation AVGN7 demonstrated that overexpressing SMAD7 (搜索) in muscle enhances muscle mass and fiber size, increases the number of type II fibers, and improves multiple metrics of muscle function including total tetanic twitch force and grip strength. The therapy works by increasing muscle protein synthesis and decreasing degradation through coordinated upregulation of ribosomal protein S6 (搜索) and translation initiation factor 4E (搜索), while downregulating muscle-specific E3 ubiquitin ligases.
Comprehensive Safety Assessment
The toxicology study evaluated AVGN7.2 (搜索) safety, biodistribution, and immunogenicity following single intravenous injections at doses ranging from 2.78×10¹² to 2.1×10¹⁴ vg/kg in C57BL/6 mice. Standard toxicology endpoints included mortality, clinical observations, body weight changes, food consumption, clinical pathology, ophthalmology, and anatomic pathology assessments.
Results showed no AVGN7.2 (搜索)-related mortality or significant adverse effects across all dose groups. Minor findings included mild to moderate edema or erythema in the inguinal area of some male mice, but these were considered non-adverse and unrelated to treatment. Hematology and serum chemistry analyses revealed only minimal, statistically insignificant differences that were attributed to normal biological variability rather than drug-related toxicity.
Based on the absence of adverse effects at any tested dose, researchers established the No Observed Adverse Effect Level (NOAEL) at the highest dose of 2.1×10¹⁴ vg/kg—a level known to elicit clinical toxicities with other AAV serotypes in human patients and animal models.
Muscle-Specific Targeting Confirmed
Biodistribution studies revealed that while AVGN7.2 (搜索) vector genomes were detected at highest levels in liver tissue, as expected with AAV6 vectors, the therapeutic protein expression remained strictly limited to striated muscle. This muscle specificity was achieved through the CK8 promoter, which prevented off-target protein expression despite vector presence in non-muscle tissues.
Western blot analysis confirmed that human SMAD7 (搜索) protein was only overexpressed in striated muscle tissues, with levels 3- to 6-fold higher in hearts and tibialis anterior muscles of treated mice by day 29. The study also identified potential biomarkers for future clinical monitoring, including elevated levels of ribosomal protein S6 (搜索) and its phosphorylated form in muscle tissues.
Immunogenicity Profile
As expected with AAV-based gene therapies, mice developed immune responses to the AAV6 capsid, presenting as early IgM responses followed by sustained IgG responses. However, no significant immune response was detected against the human SMAD7 (搜索) protein, likely due to the 98% identity and 99% similarity between human and mouse SMAD7 (搜索) orthologs.
The capsid-specific immune response would presumably prevent redosing without immunosuppression, though this limitation is considered acceptable for IBM (搜索) treatment, which would typically require only a single administration in middle-aged patients at diagnosis.
Clinical Development Path
These preclinical safety data represent a critical milestone in advancing AVGN7.2 (搜索) toward clinical trials. The therapy's excellent safety profile, combined with its muscle-specific targeting and potential to address the underlying pathophysiology of IBM (搜索), positions it as a promising candidate for treating this orphan disease indication.
Future development plans include large animal GLP toxicology studies using doses that bracket the projected clinical dose range, along with development of species-specific biodistribution and immunogenicity assays. The researchers emphasize that AVGN7.2 (搜索)'s safety profile compares favorably to other muscle-tropic AAV vectors, particularly AAV8 and AAV9, which have been associated with notable treatment-related adverse events in clinical trials.
The study's findings provide comprehensive evidence supporting AVGN7.2 (搜索)'s potential as a safe and effective treatment for inclusion body myositis (搜索) and other muscle wasting diseases (搜索), offering hope to patients facing conditions with limited therapeutic options.